The U.S. Food and Drug Administration (FDA) has cleared the launch of a Phase 2 clinical trial testing IM-101, ImmunAbs’ investigational therapy for myasthenia gravis (MG). The multicenter, placebo-controlled trial is expected to enroll up to 90 people with MG who will receive IM-101 or a placebo once monthly.
The first patient has joined a Phase 3 clinical trial assessing the safety and efficacy of Descartes-08, an investigational cell therapy for myasthenia gravis (MG) being developed by Cartesian Therapeutics. Called AURORA (NCT06799247), the trial is expected to enroll 100 adults with generalized MG (gMG), a more…
People with generalized myasthenia gravis (gMG) who were misdiagnosed at least once and who have certain disease symptoms are more likely to see an increase in disease severity, according to a recent study. Ocular symptoms and/or muscle aches after physical activity were significantly associated with a higher risk of…
Rituximab may be safe and effective in treating young children with myasthenia gravis (MG) driven by antibodies that target muscle-specific tyrosine kinase (MuSK), according to a report detailing the case of a 4-year-old girl. The girl was one of the youngest MG patients to have received rituximab, according…
Treatment with Remegen’s telitacicept over nearly six months safely reduced disease severity in adults with generalized myasthenia gravis (gMG) and helped ease these patients’ symptoms. That’s according to new data from a Phase 3 clinical trial (NCT05737160) that was presented in a late-breaking session at this year’s…
Myasthenia gravis (MG) is associated with a high personal and societal economic burden, due to work engagement and income difficulties, physician visits, hospitalizations, and medications. That’s according to a new study from Germany that analyzed responses from patient surveys on personal burden, as well as data from a claims…
People with myasthenia gravis (MG) who have more severe disease when they are diagnosed, are older at its onset, or have a thymus tumor are at a higher risk of myasthenic crises, a study from Southwest China indicates. According to the researchers, “the results underscore the critical importance…
A 39-year-old woman with severe myasthenia gravis (MG) associated with a thymoma, a thymus tumor, responded favorably to treatment with Ultomiris (ravulizumab), according to a case study from clinicians in Greece. The treatment successfully managed the woman’s rapidly evolving symptoms in the acute setting. The patient later underwent…
People newly diagnosed with myasthenia gravis (MG) in England experience a high disease burden, with about two-thirds having at least one exacerbation, or an episode of disease worsening, and approximately half having one MG-related hospitalization. That’s according to a new study led by researchers from the pharmaceutical company…
People with myasthenia gravis (MG) have a higher risk of developing cancer in organs other than the thymus, particularly in the skin and gastrointestinal tract, than people without the disease, according to a study. The incidence of such cancers tended to be higher in the five years before and…
Get regular updates to your inbox.
